CETIR Grup Medic

Barcelona, Spain

CETIR Grup Medic

Barcelona, Spain
SEARCH FILTERS
Time filter
Source Type

Humbert L.,Galgo Medical | Martelli Y.,Galgo Medical | Fonolla R.,Galgo Medical | Steghofer M.,Galgo Medical | And 4 more authors.
IEEE Transactions on Medical Imaging | Year: 2017

The 3D distribution of the cortical and trabecular bone mass in the proximal femur is a critical component in determining fracture resistance that is not taken into account in clinical routine Dual-energy X-ray Absorptiometry (DXA) examination. In this paper, a statistical shape and appearance model together with a 3D-2D registration approach are used to model the femoral shape and bone density distribution in 3D from an anteroposterior DXA projection. A model-based algorithm is subsequently used to segment the cortex and build a 3D map of the cortical thickness and density. Measurements characterising the geometry and density distribution were computed for various regions of interest in both cortical and trabecular compartments. Models and measurements provided by the '3D-DXA' software algorithm were evaluated using a database of 157 study subjects, by comparing 3D-DXA analyses (using DXA scanners from three manufacturers) with measurements performed by Quantitative Computed Tomography (QCT). The mean point-to-surface distance between 3D-DXA and QCT femoral shapes was 0.93 mm. The mean absolute error between cortical thickness and density estimates measured by 3D-DXA and QCT was 0.33 mm and 72 mg/cm3. Correlation coefficients (R) between the 3D-DXA and QCT measurements were 0.86, 0.93, and 0.95 for the volumetric bone mineral density at the trabecular, cortical, and integral compartments respectively, and 0.91 for the mean cortical thickness. 3D-DXA provides a detailed analysis of the proximal femur, including a separate assessment of the cortical layer and trabecular macrostructure, which could potentially improve osteoporosis management while maintaining DXA as the standard routine modality. © 1982-2012 IEEE.


Tebe C.,Agencia dInformacio | Tebe C.,CIBER ISCIII | del Rio L.M.,CETIR Grup Medic | del Rio L.M.,Institute Salud Carlos III | And 9 more authors.
Gaceta Sanitaria | Year: 2011

Introduction: Fragility fractures are an important public health issue. The aim of this study was to analyze the association of the main osteoporotic risk factors related to fragility fracture in a cohort of women with an indication of bone densitometry (BD). Methods: A retrospective cohort was followed-up until a fragile fracture occurred, in a population of women aged 40 to 90 years with a first visit for BD between January 1992 and February 2008. We calculated the incidence rate of fracture per 1000 women-years of follow-up, and the hazard ratio (HR) of fragile fracture using a Cox regression model. Results: A total of 49,735 women were studied. The average age of participants was 57.8 years (SD: 8.5). Of these, 3631 women (7.1%) reported a new fragility fracture in post-baseline visits. Risk factors with higher adjusted HR were age ≥ 75 years compared with age < 55 years (HR: 3.8; 95% CI: 3.3-4.4) and having a BC result evaluated as osteoporosis compared to normal (HR: 2.0; 95% CI: 1.8-2.2). A personal history of humerus, hip or vertebral fractures had an adjusted HR of 1.2 (95% CI: 1.1-1.3). Conclusions: The main risk factors for fragility fracture were advanced age, BD result and a personal history of fracture, although 74% of fractures were detected with a bone mineral density classified as normal or osteopenia. Other relevant factors were rheumatoid arthritis or having received prolonged corticosteroid therapy. © 2011 SESPAS.


Tebe Cordomi C.,Agencia dInformacio | Tebe Cordomi C.,CIBER ISCIII | del Rio L.M.,CETIR Grup Medic | Di Gregorio S.,CIBER ISCIII | And 9 more authors.
Journal of Clinical Densitometry | Year: 2013

FRAX is a fracture risk assessment tool to estimate the 10-yr probability of a major osteoporotic fracture or a hip fracture. The aim of the study was to assess the predictive ability of FRAX for major osteoporotic fracture in a cohort of Spanish women. The study was based on a retrospective cohort of women aged 40-90. yr. Patients were followed from their first bone densitometry to the first major osteoporotic fracture event (forearm, proximal humerus, clinical spine, or hip fracture) or for 10. yr whichever comes first. A total of 1231 women were included. Bone mineral density data and self-reported data on risk factors for fracture were obtained. The predictive ability of FRAX was assessed by analyzing calibration and discrimination, with the calculation of observed-to-expected (O/E) fracture ratios and the receiver operating characteristic (ROC) curve, respectively. A total of 222 women (18.1%) reported at least 1 fracture after the first assessment. The incidence of fracture was 14 (95% confidence interval [CI]: 10-17), 19 (95% CI: 15-23), 28 (95% CI: 21-36), and 67 (95% CI: 8-125) cases per 1000 woman-years in women aged <55, 55-64, 65-74, and ≥75. yr, respectively. The O/E ratio was 3.9 (95% CI: 3.4-4.5; p< 0.0001). The area under the ROC curve was 61% (95% CI: 57-65%).FRAX underestimated the risk of major osteoporotic fracture in this cohort of Spanish women, particularly in those with a low risk of fracture according to the clinical factors used in the FRAX tool. Our findings highlight the need for validation studies of FRAX in Spain. © 2013 The International Society for Clinical Densitometry.


Bonjoch A.,Foundation University | Figueras M.,Polytechnic University of Catalonia | Estany C.,Foundation University | Perez-Alvarez N.,Foundation University | And 10 more authors.
AIDS | Year: 2010

Background: Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce. Methods: We studied 671 patients with at least one dual-energy X-ray absorptiometry scan (391 of them ≥2 scans) to determine the prevalence and progression of BMD and establish related factors. Linear regression and logistic polytomic regression were used for the cross-sectional study and mixed effects and generalized estimating equations were used for the longitudinal study. Results: Osteopenia and osteoporosis were diagnosed in 47.5 and 23%, respectively. Progression to bone demineralization was observed in 28% of the patients over a median of 2.5 years (12.5% progressed to osteopenia and 15.6% to osteoporosis). In the 105 patients with at least 5 years of follow-up, progression was 47% (18% to osteopenia; 29% to osteoporosis). Factors associated with bone loss and progression were age [odds ratio (OR) 1.07; 95% confidence interval (CI) 1.05-1.08; P<0.0001], male sex (OR 2.23; 95% CI 1.77-2.8; P<0.0001), low body mass index (OR 1.14; 95% CI 1.11-1.17; P<0.0001), time on protease inhibitor (OR 1.18; 95% CI 1.12-1.24; P<0.0001), time on tenofovir (OR 1.08; 95% CI 1.03-1.14; P<0.0019), and current use of protease inhibitors (OR 1.64; 95% CI 1.35-2.04; P<0.0001). Conclusions: Our results show a high prevalence of and considerable progression to osteopenia/ osteoporosis in our cohort. Our findings support the importance of applying adequate strategies to prevent bone demineralization and of close monitoring of BMD in HIV-infected patients, specifically in at-risk patients who are taking antiretrovirals that affect bone mineralization. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Rojas J.,University of Barcelona | Lonca M.,University of Barcelona | Imaz A.,University of Barcelona | Estrada V.,Complutense University of Madrid | And 11 more authors.
HIV Medicine | Year: 2016

Objective: To assess whether changes in antiretroviral drugs other than thymidine nucleoside reverse transcriptase inhibitors (NRTI) may have a body fat impact in HIV-infected patients with lipoatrophy. Methods: Ninety-six-week phase IV, open-label, multicentre, pilot randomized trial. HIV-infected patients with moderate/severe lipoatrophy at one or more body sites despite long-term thymidine NRTI-free therapy were randomized to continue their efavirenz (EFV)-based antiretroviral regimen or to switch from EFV to lopinavir/ritonavir (LPV/r). The primary endpoint was the absolute change in limb fat mass measured by dual X-ray absorptiometry from baseline to 96 weeks. Changes in other body fat measurements, subjective perception of lipoatrophy, subcutaneous fat gene expression and plasma lipids were also assessed. Results: Thirty-three patients (73% men, median age 52 years) were recruited. At 96 weeks, absolute limb fat mass increased in the LPV/r arm vs. the EFV arm (estimated difference +1082.1 g; 95% CI +63.7 to +2103.5; P = 0.04); this difference remained significant after adjustment by gender, age, fat mass, body mass index and CD4 cell count at baseline. Subjective lipoatrophy perception scores also improved in the LPV/r arm relative to the EFV arm. Adipogenesis, glucose and lipid metabolism, and mitochondrial gene expression increased in the LPV/r arm compared with the EFV arm at 96 weeks. HDL cholesterol decreased in the LPV/r arm relative to the EFV arm. Conclusions: Switching from EFV to LPV/r in HIV-infected patients with lipoatrophy may offer further limb fat gain beyond thymidine NRTI discontinuation, although this strategy decreased plasma HDL cholesterol and caused changes in subcutaneous fat gene expression that may be associated with increased insulin resistance. © 2016 British HIV Association.


PubMed | Complutense University of Madrid, University of Barcelona, Hospital Universitario Central Of Asturias, Autonomous University of Barcelona and 3 more.
Type: Clinical Trial, Phase IV | Journal: HIV medicine | Year: 2016

To assess whether changes in antiretroviral drugs other than thymidine nucleoside reverse transcriptase inhibitors (NRTI) may have a body fat impact in HIV-infected patients with lipoatrophy.Ninety-six-week phase IV, open-label, multicentre, pilot randomized trial. HIV-infected patients with moderate/severe lipoatrophy at one or more body sites despite long-term thymidine NRTI-free therapy were randomized to continue their efavirenz (EFV)-based antiretroviral regimen or to switch from EFV to lopinavir/ritonavir (LPV/r). The primary endpoint was the absolute change in limb fat mass measured by dual X-ray absorptiometry from baseline to 96 weeks. Changes in other body fat measurements, subjective perception of lipoatrophy, subcutaneous fat gene expression and plasma lipids were also assessed.Thirty-three patients (73% men, median age 52 years) were recruited. At 96 weeks, absolute limb fat mass increased in the LPV/r arm vs. the EFV arm (estimated difference +1082.1 g; 95% CI +63.7 to +2103.5; P = 0.04); this difference remained significant after adjustment by gender, age, fat mass, body mass index and CD4 cell count at baseline. Subjective lipoatrophy perception scores also improved in the LPV/r arm relative to the EFV arm. Adipogenesis, glucose and lipid metabolism, and mitochondrial gene expression increased in the LPV/r arm compared with the EFV arm at 96 weeks. HDL cholesterol decreased in the LPV/r arm relative to the EFV arm.Switching from EFV to LPV/r in HIV-infected patients with lipoatrophy may offer further limb fat gain beyond thymidine NRTI discontinuation, although this strategy decreased plasma HDL cholesterol and caused changes in subcutaneous fat gene expression that may be associated with increased insulin resistance.


Di Gregorio S.,Cetir Grup Medic | Di Gregorio S.,Charles III University of Madrid | Del Rio L.,Cetir Grup Medic | Del Rio L.,Charles III University of Madrid | And 4 more authors.
Bone | Year: 2015

Purpose: The objective of the study was to assess longitudinal effects of different osteoporosis treatments on TBS and aBMD at lumbar spine. Method: We analyzed 390 patients (men: 72; women: 318; age>40years; mean follow-up of 20months and BMI<37kg/m2). We stratified the cohort by treatments: Naive of treatment (Naive, n=67), Calcium and Vitamin D (CaVitD, n=87), Testosterone (Te, n=36), Alendronate (AL, n=88), Risedronate (Ri, n=39), Denosumab (Dmb, n=43) and Teriparatide (PTH, n=30). The follow-up changes from baseline were normalized at 24months. Results: After 24. months, Naive group TBS decreased by 3.1% (p. <. 0.05) whereas a non-significant increase was observed for spine aBMD (δ. =. +. 0.5%). Compared to the Naive group, significant improvement (p. <. 0.05) was observed in both TBS and aBMD for Te, AL, Ri, Dmb and PTH groups and in the CaVitD group for TBS. At the end of the follow-up, significant improvement have been observed for aBMD in Te (+. 4.4%), AL (+. 4.1%), Ri (+. 4.8), D (+. 8.8%) and PTH (+. 8.8%) groups. Significant improvement was observed only in the AL (+. 1.4%), Dmb (+. 2.8%) and PTH (+. 3.6%) groups for TBS. Conclusion: As expected, TBS of Naive subjects decreased with age. As expected a TBS preservation has been observed under AL and Ri. Te and CaVitD effects on TBS were evaluated for the first time: a similar preservation effect has been observed. A significant TBS increase was observed under Denosumab and PTH. TBS could be a useful tool to monitor treatment effects. © 2015 Elsevier Inc.


Humbert L.,University Pompeu Fabra | Humbert L.,Networking Biomedical Research Center Bioengineering | Whitmarsh T.,University Pompeu Fabra | Whitmarsh T.,Networking Biomedical Research Center Bioengineering | And 5 more authors.
Medical Physics | Year: 2012

Purpose: Dual-energy x-ray absorptiometry (DXA) is used in clinical routine to provide a two-dimensional (2D) analysis of the bone mineral density (BMD). 3D reconstruction methods from 2D DXA images could improve the BMD analysis. To find the optimal configuration that should be used in clinical routine, this paper relies on a 3D reconstruction method from DXA images to compare the accuracy that can be obtained from one single-view and from multiview DXA images (two to four projections). Methods: The 3D reconstruction method uses a statistical model and a nonrigid registration technique to recover in 3D the shape and the BMD distribution of the proximal femur. The accuracy was evaluated in vivo by comparing 3D reconstructions obtained from simulated DXA images of 30 patients (using between one and four DXA views) with quantitative computed tomography reconstructions. Results: This comparison showed that the use of one single DXA provides accurate 3D reconstructions (mean shape accuracy of 1.0 mm and BMD distribution errors of 7.0). Among the multiview configurations, the use of two views (0° and 45°) was the best compromise, increasing the accuracy of pose (mean accuracy of 0.7°/1.2°/0.9° against 1.0°/3.5°/3.3° for the single view), reducing slightly the BMD errors (5.7) while maintaining the same shape accuracy. Conclusions: The use of two views constitutes an interesting configuration when multiview DXA devices are available in clinical routine. However, the use of only one single view remains an accurate solution to recover the shape and the BMD distribution in 3D, with the advantage of a higher potential for clinical translation. © 2012 American Association of Physicists in Medicine.


Del Rio L.M.,CETIR Grup Medic | Winzenrieth R.,Bordeaux University Hospital Center | Cormier C.,Hospital Cochin | Di Gregorio S.,CETIR Grup Medic
Osteoporosis International | Year: 2013

Bone mineral density (BMD) as assessed by dual energy X-ray absorptiometry (DXA) constitutes the gold standard for osteoporosis diagnosis. However, DXA does not take into account bone microarchitecture alterations. Introduction: The aim of our study was to evaluate the ability of trabecular bone score (TBS) at lumbar spine to discriminate subjects with hip fracture. Methods: We presented a case-control study of 191 Spanish women aged 50 years and older. Women presented transcervical fractures only. BMD was measured at lumbar spine (LS-BMD) using a Prodigy densitometer. TBS was calculated directly on the same spine image. Descriptive statistics, tests of difference and univariate and multivariate backward regressions were used. Odds ratio (OR) and the ROC curve area of discriminating parameters were calculated. Results: The study population consisted of 83 subjects with a fracture and 108 control subjects. Significant lower spine and hip BMD and TBS values were found for subjects with fractures (p < 0.0001). Correlation between LS-BMD and spine TBS was modest (r = 0.41, p < 0.05). LS-BMD and TBS independently discriminate fractures equally well (OR = 2.21 [1.56-3.13] and 2.05 [1.45-2.89], respectively) but remain lower than BMD at neck or at total femur (OR = 5.86 [3.39-10.14] and 6.06 [3.55-10.34], respectively). After adjusting for age, LS-BMD and TBS remain significant for transcervical fracture discrimination (OR = 1.94 [1.35-2.79] and 1.71 [1.15-2.55], respectively). TBS and LS-BMD combination (OR = 2.39[1.70-3.37]) improved fracture risk prediction by 25 %. Conclusion: This study shows the potential of TBS to discriminate subjects with and without hip fracture. TBS and LS-BMD combination improves fracture risk prediction. Nevertheless, BMD at hip remains the best predictor of hip fracture. © 2012 International Osteoporosis Foundation and National Osteoporosis Foundation.


PubMed | CETIR Grup Medic
Type: Evaluation Studies | Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA | Year: 2013

Bone mineral density (BMD) as assessed by dual energy X-ray absorptiometry (DXA) constitutes the gold standard for osteoporosis diagnosis. However, DXA does not take into account bone microarchitecture alterations.The aim of our study was to evaluate the ability of trabecular bone score (TBS) at lumbar spine to discriminate subjects with hip fracture.We presented a case-control study of 191 Spanish women aged 50 years and older. Women presented transcervical fractures only. BMD was measured at lumbar spine (LS-BMD) using a Prodigy densitometer. TBS was calculated directly on the same spine image. Descriptive statistics, tests of difference and univariate and multivariate backward regressions were used. Odds ratio (OR) and the ROC curve area of discriminating parameters were calculated.The study population consisted of 83 subjects with a fracture and 108 control subjects. Significant lower spine and hip BMD and TBS values were found for subjects with fractures (p < 0.0001). Correlation between LS-BMD and spine TBS was modest (r = 0.41, p < 0.05). LS-BMD and TBS independently discriminate fractures equally well (OR = 2.21 [1.56-3.13] and 2.05 [1.45-2.89], respectively) but remain lower than BMD at neck or at total femur (OR = 5.86 [3.39-10.14] and 6.06 [3.55-10.34], respectively). After adjusting for age, LS-BMD and TBS remain significant for transcervical fracture discrimination (OR = 1.94 [1.35-2.79] and 1.71 [1.15-2.55], respectively). TBS and LS-BMD combination (OR = 2.39[1.70-3.37]) improved fracture risk prediction by 25 %.This study shows the potential of TBS to discriminate subjects with and without hip fracture. TBS and LS-BMD combination improves fracture risk prediction. Nevertheless, BMD at hip remains the best predictor of hip fracture.

Loading CETIR Grup Medic collaborators
Loading CETIR Grup Medic collaborators